h~causes of fibrocystic changes are as yet uncertain, although it is presumed that hormonal anatlOns are contributory (Haagensen 1971) . There is some evidence that serum oestrogen {vels may be high in patients with benign mastopathy. Early reports oflow progesterone levels a~e been denied by Golinger (1978) who produced detailed results on larger groups of P~hents.
Recently, elevated prolactin levels have been observed in patients with fibrocystic disease (Cole et al. 1977) . This uncertainty regarding the cause is reflected in the wide variety of treatments used for this condition.
B Two further drugs have recently been recommended for the treatment of cyclical mastalgia.
romocryptine is a dopamine agonist and prolactin inhibitor. Danazol is a pituitary gonadotrophin inhibitor, derived from ethisterone, with mild androgenic activity. As present treatment of cyclical mastalgia is, in general, unsatisfactory, it was decided to compare the efficacy of these two new drugs. In view of their known side effects, a true double-blind, crossover, controlled trial was not feasible and a sequential study was therefore chosen.
Methods
Over a two-year period, 20 patients who attended the Royal Marsden Hospital Breast Unit we~e considered suitable for this study. All had severe cyclical mastalgia, which had not been reheved by diuretics or a variety of other treatments.
The patients were thoroughly investigated to exclude any underlying pathology, using !he~ography, xeroradiography, fine needle aspiration cytology and frequent clinical exam-lUahon. The agerange of the patients studied was 24-47 years, with a mean of 38 years.
After assessment, patients were started on a dose of 1.25 mg bromocryptine daily and this was. increased by 1.25 mg every three days until they were taking 2.5 mg twice daily.
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were prescribed over this period where necessary. Treatment was stopped after h ree months. A questionnaire assessing the change in breast symptoms and the side effects of e drug was completed by each patient. IOAfter at least one month's rest from treatment, the patients commenced taking danazol ofig four times daily for a further three months. At the end of this period, another questionnaire was completed.
During the study each patient was seen monthly in the week preceding the expected date of enstruation.
Symptoms and side effects were recorded and blood was taken for prolactin (~el s.
Results
Sixteen patients completed three months' treatment with broniocryptine and 10 patients completed three months' treatment with danazol (Table 1) . Bromocryptine causes increased fertility, nausea, constipation and mental changes, but these effects are reduced by starting with a low dose. Most patients had few side effects after being on the drug for two weeks and only one patient discontinued because of side effects.
Danazol usually causes amenorrhoea or infrequent periods, but other side effects are acne, increased hair growth, deepening voice, change in libido and muscular pains. Patients found these side effects more distressing and in nearly all cases they preferred bromocryptine.
Statistical analysis showed a highly significant fall in prolactin levels whilst on treatment with bromocryptine but not with danazol (P<O.OOI and P>O.05, respectively) when compared by Student's t test ( Figure I 
Discussion
It has long been held that cyclical mastalgia is a psychosomatic disorder (Patey 1949).A recent investigation, however, has shown no psychological differences between these patients and normal controls (Preece et al. 1976) .
Diuretics are widely used on the assumption that fluid retention is a cause. However, it has been shown that total body water is not increased premenstrually (Preece et al. 1975) and little work has been done on the effectiveness of diuretics.
Hormonal preparations have been used for over forty years. Oestrogens tend to worsen the symptoms, whilst androgens relieve symptoms in 50% of patients. However, hair growth, voice changes and ammenorrhoea make this an unacceptable form of treatment (Atkins 1940) . Progestogens, such as norethisterone, can give considerable relief when given in the premenstruum (Davis 1968 ). The contraceptive pill may cause these symptoms, or they may develop on cessation of the treatment with relief on restarting (Balin & Wan 1970). Low-dose radiotherapy, though very effective, is no longer used because of its carcinogenic effect.
.This trial shows that 70% of patients with persistent, severe symptoms will get relief of pain WI~h both bromocryptine and danazol. Lauersen & Wilson (1976) claimed an 87% success rate U~l Og danazol, and Schulz et al. (1975) stated that 87% of their patients showed improvement With bromocryptine.
. t is uncertain whether the reduction in the serum prolactin level is directly related to the relIefof symptoms, since levels fell in those patients who obtained no relief. The prolactin levels remained within the normal laboratory range in patients treated with danazol.
Summary
In a sequential study to compare the efficacy ofbromocryptine and danazol in the treatment of sev:re cyclical mastalgia, 70% of patients in both groups were relieved of their symptoms. atIents tended to prefer bromocryptine because of its limited side effects. There was a significant fall in prolactin levels with bromocryptine, but not with danazol.
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